Effects of selective calcium-permeable AMPA receptor blockade by IEM 1460 on psychotomimetic-induced hyperactivity in the mouse
Authors:
- 21 December 2017
- journal article
- research article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 125 (4) , 705-711
Abstract
Diminished glutamate neurotransmission via the N-methyl-d-aspartate type glutamate receptor (NMDAR) has been considered to be involved in the pathophysiology of schizophrenia based upon the observation that the antagonists and autoantibodies of NMDAR cause positive, negative and cognitive symptomatologies similar to those of schizophrenia. The possible reduced extracellular levels of d-serine by overstimulation of the calcium-permeable α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate glutamate receptor (CP-AMPAR) following the NMDAR hypofunction-induced compensatory increase in the glutamate release could aggravate the NMDAR hypofunction in the brain of the drug- or antibody-associated psychoses and schizophrenia, because d-serine is an intrinsic coagonist for the NMDAR. To obtain an insight into the therapeutic approach to such a glutamate-linked psychotic state, we have studied the effects of the systemic administration of the CP-AMPAR-selective antagonist, IEM 1460 (N,N,N-trimethyl-5- [(tricyclo[3.3.1.13,7]dec-1-ylmethyl)amino]-1-pentanaminium bromide hydrobromide), on the hyperactivity following an injection of a schizophrenomimetic NMDAR antagonist, phencyclidine, in the mouse. The subcutaneous IEM 1460 application produced a dose-dependent inhibition of the increased movement counts after the subcutaneous injection of phencyclidine. This inhibiting influence was also seen on the hyperactivity elicited by another NMDAR antagonist, dizocilpine. Moreover, the IEM 1460 administration attenuated the ability of a schizophrenomimetic dopamine agonist, methamphetamine, to increase spontaneous movements. These findings indicate that dysregulation of the CP-AMPAR could, at least in part, be implicated in the glutamate pathology of schizophrenia and/or related psychotic symptoms and be a potential target for the development of their novel treatment.Keywords
Funding Information
- Tokyo Medical and Dental University funds (Not applicable)
This publication has 36 references indexed in Scilit:
- Modulation of extracellular d-serine content by calcium permeable AMPA receptors in rat medial prefrontal cortex as revealed by in vivo microdialysisInternational Journal of Neuropsychopharmacology, 2013
- Cell Selective Conditional Null Mutations of Serine Racemase Demonstrate a Predominate Localization in Cortical Glutamatergic NeuronsCellular and Molecular Neurobiology, 2012
- Selective Inhibition of Striatal Fast-Spiking Interneurons Causes DyskinesiasThe Journal of Neuroscience, 2011
- From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for TreatmentNeuropsychopharmacology, 2011
- Short-term selective breeding for High and Low prepulse inhibition of the acoustic startle response; pharmacological characterization and QTL mapping in the selected linesPharmacology Biochemistry and Behavior, 2008
- Dizocilpine (MK-801) elicits a tetrodotoxinsensitive increase in extracellular release of dopamine in rat medial frontal cortexNeurochemistry International, 1995
- Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in ratsJournal of Neural Transmission, 1995
- Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonistsLife Sciences, 1993
- Competitive and non-competitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitizationLife Sciences, 1992
- Neuropharmacology of Phencyclidine: Basic Mechanisms and Therapeutic PotentialAnnual Review of Pharmacology and Toxicology, 1990